dc.creator | Zafeiropoulos S., Farmakis I., Kartas A., Arvanitaki A., Pagiantza A., Boulmpou A., Tampaki A., Kosmidis D., Nevras V., Markidis E., Papadimitriou I., Vlachou A., Arvanitakis K., Miyara S.J., Ziakas A., Molmenti E.P., Kassimis G., Zanos S., Karvounis H., Giannakoulas G. | en |
dc.date.accessioned | 2023-01-31T11:38:09Z | |
dc.date.available | 2023-01-31T11:38:09Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.atherosclerosis.2021.03.013 | |
dc.identifier.issn | 00219150 | |
dc.identifier.uri | http://hdl.handle.net/11615/80929 | |
dc.description.abstract | Background and aims: Achieving the low-density lipoprotein cholesterol (LDL-C) goal following an acute coronary syndrome (ACS) is a milestone often missed due to suboptimal adherence to secondary prevention treatments. Whether improved adherence could result in reduced LDL-C levels is unclear. We aimed to evaluate whether an educational-motivational intervention increases long-term lipid-lowering therapy (LLT) adherence and LDL-C goal attainment rate among post-ACS patients. Methods: IDEAL-LDL was a parallel, two-arm, single-center, pragmatic, investigator-initiated randomized controlled trial. Hospitalized patients for ACS were randomized to a physician-led integrated intervention consisting of an educational session at baseline, followed by regular motivational interviewing phone sessions or usual care. Co-primary outcomes were the LLT adherence (measured by Proportion of Days Covered (PDC); good adherence defined as PDC>80%), and LDL-C goal (<70 mg/dl or 50% reduction from baseline) achievement rate at one year. Results: In total, 360 patients (mean age 62 years, 81% male) were randomized. Overall, good adherence was positively associated with LDL-C goal achievement rate at one year. Median PDC was higher in the intervention group than the control group [0.92 (IQR, 0.82–1.00) vs. 0.86 (0.62–0.98); p = 0.03] while the intervention group had increased odds of good adherence (odds ratio: 1.76 (95% confidence interval 1.02 to 2.62; p = 0.04). However, neither the LDL-C goal achievement rate (49.6% in the intervention vs. 44.9% in the control group; p = 0.49) nor clinical outcomes differed significantly between the two groups. Conclusions: Α multifaceted intervention improved LLT adherence in post-ACS patients without a significant difference in LDL-C goal attainment. © 2021 Elsevier B.V. | en |
dc.language.iso | en | en |
dc.source | Atherosclerosis | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103258408&doi=10.1016%2fj.atherosclerosis.2021.03.013&partnerID=40&md5=a420031b2aa200ccf4b7a093d6383ae1 | |
dc.subject | angiotensin receptor antagonist | en |
dc.subject | antilipemic agent | en |
dc.subject | antithrombocytic agent | en |
dc.subject | beta adrenergic receptor blocking agent | en |
dc.subject | dipeptidyl carboxypeptidase inhibitor | en |
dc.subject | ezetimibe | en |
dc.subject | high density lipoprotein cholesterol | en |
dc.subject | hydroxymethylglutaryl coenzyme A reductase inhibitor | en |
dc.subject | low density lipoprotein cholesterol | en |
dc.subject | triacylglycerol | en |
dc.subject | low density lipoprotein cholesterol | en |
dc.subject | acute coronary syndrome | en |
dc.subject | adult | en |
dc.subject | adverse event | en |
dc.subject | aged | en |
dc.subject | all cause mortality | en |
dc.subject | Article | en |
dc.subject | bleeding | en |
dc.subject | body mass | en |
dc.subject | cholesterol blood level | en |
dc.subject | clinical outcome | en |
dc.subject | controlled study | en |
dc.subject | diabetes mellitus | en |
dc.subject | drug safety | en |
dc.subject | dyslipidemia | en |
dc.subject | exercise | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | goal attainment | en |
dc.subject | healthy lifestyle | en |
dc.subject | heart failure | en |
dc.subject | heart infarction | en |
dc.subject | high density lipoprotein cholesterol level | en |
dc.subject | hospital discharge | en |
dc.subject | hospital patient | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | incidence | en |
dc.subject | intention to treat analysis | en |
dc.subject | laboratory test | en |
dc.subject | low density lipoprotein cholesterol level | en |
dc.subject | major adverse cardiac event | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | medication compliance | en |
dc.subject | motivational interviewing | en |
dc.subject | myalgia | en |
dc.subject | outcome assessment | en |
dc.subject | patient compliance | en |
dc.subject | patient education | en |
dc.subject | prescription | en |
dc.subject | priority journal | en |
dc.subject | randomized controlled trial | en |
dc.subject | risk factor | en |
dc.subject | sample size | en |
dc.subject | screening | en |
dc.subject | secondary prevention | en |
dc.subject | smoking | en |
dc.subject | telemedicine | en |
dc.subject | telephone interview | en |
dc.subject | triacylglycerol blood level | en |
dc.subject | acute coronary syndrome | en |
dc.subject | dyslipidemia | en |
dc.subject | middle aged | en |
dc.subject | Acute Coronary Syndrome | en |
dc.subject | Cholesterol, LDL | en |
dc.subject | Dyslipidemias | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Secondary Prevention | en |
dc.subject | Elsevier Ireland Ltd | en |
dc.title | Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial | en |
dc.type | journalArticle | en |